Canadian innovation will give patients affordable, non-invasive, accurate test for cancer or infectious diseases; R&D team to remain in Toronto discovery district
TORONTO and SAN FRANCISCO (May 3, 2016) — Miroculus, a San Francisco-based biotechnology company specializing in microRNA-based diagnostics, today announced an agreement to acquire Toronto-based Kapplex Inc. The Canadian company’s proprietary Digital Microfluidic (DMF) platform is built upon the research of Dr. Aaron Wheeler, a world-leader in microfluidics research at the University of Toronto.
This announcement was covered in GenomeWeb and PeHub.
This op-ed on Canadian biotechnology and the knowledge economy appeared in The Hill-Times (subscription required), Canada's politics and government newsweekly, September 9:
Obesity, cancer, heart disease and stroke, diabetes, Parkinson’s disease, Alzheimer’s, or the more general stresses of an aging population: no matter which area of concern holds our collective gaze from moment to moment, improving health outcomes and healthcare is the No. 1 challenge for the world’s economy.
Canada has the holistic approach and translational research necessary to address health care’s pervasive ...
September 9, 2013
in Baycrest Centre for Geriatric Care, Centre for Addiction and Mental Health (CAMH), DLVR Therapeutics Inc, Encycle Therapeutics, Holland Bloorview Kids Rehabilitation Hospital, Kapplex, Licenseable Technologies, MaRS Discovery District, Media Coverage, Member Institutions, News, Partnerships, Portfolio, Ryerson University, Sinai Health, St. Michael's Hospital, Start-Up Companies, Sunnybrook Health Sciences Centre, The Hospital for Sick Children (SickKids), The Ontario Institute for Cancer Research (OICR), TIAP Staff, University Health Network, University of Toronto, Women's College Hospital, Xagenic, York University
MaRS Innovation (MI) seeks applicants for the Medical Sciences Proof-of-Principle (MSc PoP) program, which supports early-stage medical science technologies and allows their founding teams to conduct crucial proof-of-principle work.
Through the two-year MSc POP program, MI will distribute funding awards to qualified applicants within its membership on behalf of the Ministry of Research and Innovation (MRI). Funds are available in $25,000 or $75,000 grants.
“At MaRS Innovation, the PoP program functions as a kind of internal Dragons' Den,” says Dr. Raphael Hofstein, president ...
September 4, 2013
in BresoTec Inc., DLVR Therapeutics Inc, Encycle Therapeutics, Funding or Fundraising-Announcements, Government Partners, Kapplex, Licenseable Technologies, Member Institutions, News, Partnerships, Portfolio, ScarX Therapeutics, Start-Up Companies, TIAP Staff
GEN Magazine (Genetic Engineering and Biotechnology News) featured the microfluidics research of Dr. Aaron Wheeler on November 15, 2012.
Wheeler, Canada Research Chair of Bioanalytical Chemistry and an associate professor at the University of Toronto, has made an invention disclosure to MaRS Innovation; Kapplex is the start-up company created to commercialize his research. (more…)